Introduction {#Sec1}
============

Bipolar disorder is a chronic disease characterized by periods of mania or hypomania (episodes of elevated moods, extreme irritability, decreased sleep, and increased energy), depression (overwhelming feelings of sadness, anhedonia, suicidal thoughts) or a combination of both (named as mixed state). The exact cause of the condition is unknown, but genetic, physiological, neurological, psychosocial, and environmental factors may be involved. According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, the diagnosis of bipolar type I requires the presence or the history of at least one manic or mixed episode, whereas bipolar disorder type II differs from type I only by the presence of hypomania but no manic episodes \[[@CR1]\].

The prevalence of bipolar I disorder in Italy is estimated to be approximately 1--2%, even if the true prevalence is likely to be much higher because it is frequently under-diagnosed, largely due to the fact that it is difficult to diagnose correctly \[[@CR2]\]. Because bipolar disorder is one of the leading causes of disability, especially in active populations, it represents an important economic burden on society \[[@CR3]\]. A study evaluating the cost of bipolar disorder in the UK has estimated a cost of £198.7 million per year, with hospitalization accounting for the largest component of direct costs \[[@CR4]\].

Mixed episodes are a common feature of bipolar I disorder and they are associated with more severe symptoms and outcomes \[[@CR5], [@CR6]\]; moreover, this type of episode tends to last longer than manic and depressive episodes \[[@CR7]\] and is more commonly associated with substance abuse, anxiety disorders, and suicidality \[[@CR8]--[@CR10]\]. Treatment of bipolar mixed states is often challenging as response is usually poorer than in manic or depressive episodes \[[@CR11]\] and involves the use of lithium (Li), sodium valproate (VPA), and second-generation antipsychotics (SGAs) \[[@CR12]\]. Currently, the best evidence for efficacy as monotherapy for the acute treatment of mixed state is provided for anticonvulsants followed by the atypical antipsychotics: aripripazole, asenapine (ASE), paliperidone, and ziprasidone \[[@CR13]\]. There was also very strong evidence for the use of olanzapine (OLA) as monotherapy or as add-on to Li or VPA \[[@CR13]\].

In 2013, the first meta-analysis of the efficacy of SGAs in mixed episodes was published, suggesting that some of these drugs are effective in reducing not only manic but also depressive symptoms in patients with mixed episodes \[[@CR14]\]. SGAs, particularly ASE, OLA, aripriprazole, paliperidone, risperidone, and ziprasidone were reported to be efficacious on maniac symptoms of mixed episodes, while ASE and OLA also appear to be moderately efficacious in treating depressive symptoms of mixed episodes \[[@CR14], [@CR15]\].

ASE is a new SGA developed and approved in the USA for the acute treatment, as monotherapy or adjunctive therapy with either Li or VPA, of manic or mixed episodes associated with bipolar I disorder. Whether used as monotherapy or as adjunctive therapy with Li or VPA, the use of ASE in responding patients is generally recommended by the Food and Drug Administration to be continued beyond the acute response \[[@CR16]\]. In Europe, in September 2010, the European Medicines Agency has authorized the marketing of this molecule for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.

Focusing on mixed episode patients, Azorin et al. \[[@CR17]\] assessed the efficacy of ASE using post hoc analyses on pooled data from two identical 3-week, randomized, double-blind, placebo- and OLA-controlled trials \[[@CR18], [@CR19]\] and their 9-week double-blind, OLA-controlled extension study \[[@CR20]\]. At week three, ASE was found to be significantly superior to both placebo and OLA both on manic and depressive symptoms improving Montgomery--Åsberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) scores. At week 12, further decrease in YMRS and in MADRS total scores was observed with ASE, although not reaching a statistically significant difference. Although no statistically significant difference was observed between ASE and OLA in composite response rate or mean reduction on either score, these findings suggest a potential difference in the way the two drugs work in mixed episodes.

Even though cost-effectiveness of different SGAs in the treatment of patients experiencing a manic episode associated with bipolar I disorder has been studied in numerous analyses and in different contexts \[[@CR21]--[@CR26]\], only a few studies \[[@CR27], [@CR28]\] have explored the role of these drugs in patients with mixed episodes.

The current study evaluates from an Italian National Health Service (NHS) perspective, the cost-effectiveness of ASE compared to OLA in the treatment of patients experiencing mixed episodes associated with bipolar I disorder. Comparison against SGAs was only possible with OLA due to lack of randomized studies comparing efficacy of ASE versus other antipsychotics in the treatment of the subpopulation with mixed episodes. Furthermore, OLA was the best comparator based on proven efficacy and market-share \[[@CR13]\].

Methods {#Sec2}
=======

The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Model Introduction {#Sec3}
------------------

The pharmacoeconomic model was developed to simulate the management of Italian bipolar I patients with mixed episodes over a five-year time horizon by combining clinical parameters with resource utilization.

An expert panel, composed of five psychiatrists from different Italian regions and two health economists from an independent agency, was responsible for adapting a model developed by Sawyer et al. \[[@CR27]\] from the UK into an Italian perspective.

Efficacy was informed by a post hoc analysis of two short-term clinical trials, with response measured as a composite MADRS and YMRS \[[@CR17]\]. Probabilities of discontinuation and relapse to manic, mixed, and depressive episodes were sourced from published meta-analyses \[[@CR29], [@CR30]\].

The primary outcome measure of the economic evaluation is the incremental cost-effectiveness ratio (ICER), where effectiveness is measured in terms of quality-adjusted life years (QALYs) gained.

Because costs were considered from the Italian NHS perspective, only direct medical costs, expressed in Euro, could be evaluated. The pharmacoeconomic model was developed using Microsoft Office Excel 2007 (Microsoft Corporation, Albuquerque, NM, USA) software.

Description of Model {#Sec4}
--------------------

The model comprises an acute phase and a maintenance phase. The acute phase (Fig. [1](#Fig1){ref-type="fig"}) is designed using a standard decision tree model, and it covers the three three-week initial treatment periods. The maintenance phase is designed using a Markov model, and it follows patients for four-week cycles for a five-year follow-up period as their condition stabilizes and the goal of treatment shift into relapse prevention. A survey on treatment guidelines \[[@CR31]\] demonstrates a lack of consensus regarding the appropriate time to change treatment strategies in case of partial or non-response during an acute manic episode, with recommendations ranging from 2 to 12 weeks. In the absence of firm evidence and given the high risk of suicide in mixed episodes, a shorter duration (3 weeks) during which to assess response to treatment was considered appropriate.Fig. 1Acute phase model structure

Hypothetical patients enter the acute phase of the model experiencing a mixed episode being allocated to either ASE or OLA treatment arms. Non-responder patients will have an adjunctive therapy with VPA (ASE/OLA + VPA; 2nd line), and, if they are still not responding for the 2nd line, a switch to adjunctive Li (ASE/OLA + Li; 3rd line). The sequence of adjunctive therapy with VPA as 2nd line and Li as third line was based on the fact that most guidelines mention the superiority of VPA over Li to treat mixed episodes \[[@CR13]\]. These assumptions were informed by clinical expert opinion.

After the 9-week model acute phase, patients non-respondent to any of the treatment lines enter the Markov model as "Non-responder" on triple therapy (ASE/OLA + VPA + Li). If the response criteria are met for any treatment lines, patients enter directly in the maintenance Markov model in the "Subacute on Tx" health state.

The maintenance phase of the economic model (Fig. [2](#Fig2){ref-type="fig"}) is designed to follow hypothetical patients for 5 years after the index mixed episode, irrespective of whether they did or did not respond to treatment during the acute phase. Five years was deemed a sufficient length of time by clinical experts to capture the longer-term aspects of bipolar disorder treatment, such as stabilization after an acute episode, possible discontinuation of therapy, management and prevention of relapse episodes, and mortality.Fig. 2Maintenance phase model structure. *TX* treatment, *AA* atypical antipsychotic

As stated above, patients who have responded to either monotherapy or adjunctive treatments (1st-, 2nd-, or 3rd-line responders) in the acute phase enter the maintenance phase of the economic model in a subacute health state (i.e., a transitory state in which all responding patients must pass before reach stability), whereas patients who have not responded to any therapy in the acute phase will enter the maintenance phase as non-responders.

Patients will stay in these health states until they respond to treatment (if non-responders, transition from "Non-responder" state to "Subacute on Tx" state) and achieve euthymia (transition from "Subacute on Tx" to "Stable on atypical antipsychotic \[AA\] Tx"). Once patients achieve euthymia while on treatment, they may discontinue treatment with SGA remaining with VPA alone or Li alone (defined minimal treatment and represented in the model as "Stable minimal Tx" state). Stable patients (either on regular antipsychotic treatment or on the minimal treatment described above) can relapse and experience a manic, mixed, or depressive episode. Following relapse, patients across both arms switch to treatment with quetiapine (QTP) + VPA or QTP + Li (a 50/50 split is assumed), remaining on this treatment until the end of the modeled time horizon. This simplified approach ensures that all patients follow the same long-term prognosis and costs. At any point in the model, patients can die.

Model Parameters {#Sec5}
----------------

### Response, Relapse, Discontinuation, and other Probabilities {#Sec6}

Response to the acute phase with first line monotherapy (ASE or OLA) is defined in this model as ≥50% improvement from baseline in the YMRS and MADRS scores within 3 weeks, and sourced from the post hoc analysis of the ARES trial on mixed patients \[[@CR17]\].

Comparative response rates for ASE and OLA in combination with VPA or Li on the composite YMRS and MADRS outcome are not available from clinical trial data; therefore, for the adjunctive therapies (2nd and 3rd line treatments), differently from the UK model in which 95% confidence intervals upper limits were used, the authors applied the ASE + VPA/Li response data from Apollo 12 (Clinicaltrials.gov \#NCT00145470) trial assuming the same response for both ASE and OLA (Table [1](#Tab1){ref-type="table"}) \[[@CR32]\]. This assumption was deemed reasonable by clinical expert opinion.Table 1Response rates, annual risks of relapse, treatment discontinuation probabilities, and incidence values for weight gain and EPSTreatment drugResponse (95% CI)SourceResponse rates ASE0.463 (0.340; 0.589)\[[@CR17]\] OLA0.375 (0.274; 0.485)\[[@CR17]\] ASE + VPA/Li0.342 (0.268; 0.416)\[[@CR32]\] OLA + VPA/Li0.342 (0.268; 0.416)Assumed the same as ASE + VPA/LiTreatment drugManic/MixedDepressionSourceAnnual risks of relapse ASE0.080.14Assumed the same as OLA OLA0.080.14\[[@CR30]\] VPA0.230.05\[[@CR30]\] Li0.200.07\[[@CR30]\] Li + VPA0.230.05Assumed to be the max value between VPA and Li QTP + Li/VPA0.140.22\[[@CR33]\] Minimal TX0.2150.06Average of Li and VPATreatment drugProbabilitySourceTreatment discontinuation probabilities Placebo0.017\[[@CR34]\] ASE0.013Assumed the same as OLA OLA0.013\[[@CR29]\] VPA0.014\[[@CR29]\] Li0.016\[[@CR29]\] Li + VPA0.014Assumed to be the max value between VPA and Li QTP + Li/VPA0.012\[[@CR29]\]Treatment drugWeight gainEPSSourceIncidence values for weight gain and EPS ASE0.1380.112\[[@CR17]\] OLA0.07640.098\[[@CR17]\] VPA0.0790.032\[[@CR37]\] Li0.0290.028\[[@CR38]\] QTP + VPA + Li0.1440.0092\[[@CR33]\]*ASE* asenapine, *EPS* extrapyramidal symptoms, *Li* lithium, *OLA* olanzapine, *QTP* quetiapine, *VPA* sodium valproate

The annual risks of relapse used in the maintenance phase model for each treatment arm are reported in Table [1](#Tab1){ref-type="table"}. Most of these values were sourced from a systematic review and network meta-analysis by Soares-Weiser et al. \[[@CR30]\]. As ASE was not available in this review, it was assumed that the annual risk of relapse for ASE was the same as for OLA. Similarly, as no data were available on the efficacy of combination therapies in relapse prevention, it was assumed that risk of relapse was related to the last added treatment.

Since probabilities of relapse from Soares-Weiser et al. \[[@CR30]\] were stratified by manic/mixed or depressive episode, the model needed a further breakdown between patients experiencing a recurrent manic episode versus a recurrent mixed episode. For this reason, the authors applied the probability of a relapse split between mania and mixed episodes from the study by Vieta and colleagues (53.3% mania and 46.7% mixed) \[[@CR33]\].

Treatment discontinuation in the model is defined as patients discontinuing their antipsychotic treatment and moving on to a "minimal treatment", which was assumed to be VPA alone for 50% of patients and Li alone for the other 50%. As in the UK model, probability of discontinuing treatment with the initial drug during periods of disease stability was calculated by applying a risk ratio from a published meta-analysis of clinical trials \[[@CR34]\] to an underlying baseline probability of discontinuing on placebo. The placebo discontinuation rates are based on a published discrete-event simulation model for patients with acute bipolar depression \[[@CR29]\]. Again, as ASE-treatment discontinuation risk was not available in the meta-analysis, it was assumed that the treatment discontinuation probability for ASE was the same as for OLA (Table [1](#Tab1){ref-type="table"}).

Patients who failed to respond to the 1st-, 2nd-, and 3rd-line treatments in the acute phase enter the maintenance phase as non-responders and on triple therapy (AA + VPA + Li). Due to lack of data, the authors have assumed a 35% per cycle probability of reaching the subacute health state and varied the base case probability in a sensitivity analysis from 0% to 100%.

The subacute health state was implemented in the model as a temporary tunnel state, through which responding patients must transition before achieving stable euthymia. From this temporary tunnel state, a monthly probability of achieving euthymia was estimated to be 60% based on expert opinion. Also this probability has been tested by the authors with a sensitivity analysis from 0% to 100%.

The mortality risk, stratified by causes (suicide and non-suicide), was calculated starting from the interim life tables for Italy \[[@CR35]\] and applying the general population annual risk of suicide from the same source. Finally, the authors applied standardized mortality ratios for suicide (11.53) and non-suicide (1.69) retrieved from Angst et al. \[[@CR36]\] to define the mortality risk among patients with bipolar I disorder.

### Adverse Event {#Sec7}

The model incorporates two common adverse events due to antipsychotic medication: weight gain and extrapyramidal symptoms (EPS), whose incidences, that are different according to drug regimen, were retrieved from several trials \[[@CR17], [@CR33], [@CR37], [@CR38]\]. Weight gain is associated with all bipolar disorder drugs; so, this adverse event was associated with all drugs. For combination therapies, the incidence of weight gain is set to equal that of the drug with the highest incidence. EPS is typically associated with atypical antipsychotics and not with mood stabilizers; so, EPS are assumed to occur only during the atypical antipsychotics treatment. Both adverse events are assumed to occur independently. The incidence values for weight gain and EPS are reported in Table [1](#Tab1){ref-type="table"}.

### Utilities {#Sec8}

Utility values for the model health states and adverse events were derived from the UK model \[[@CR24]\], except for inpatient and outpatient mixed episodes utilities; since no data were available in literature, the authors agreed to set the same values as those set for mania (Table [2](#Tab2){ref-type="table"}).Table 2Utility valuesConditionUtility valueSourceSubacute0.8\[[@CR39]\]Stable0.84\[[@CR17]\]Mania IP0.245\[[@CR39]\]Mania OP0.585\[[@CR39]\]Mixed IP0.245Assumed the same as Mania IPMixed OP0.585Assumed the same as Mania OPDepression IP0.29\[[@CR39]\]Depression OP0.605\[[@CR46]\]Weight gain0.825\[[@CR47]\]EPS0.722\[[@CR47]\]*EPS* extrapyramidal symptoms, *IP* inpatient, *OP* outpatient

The utility values of the general population applied in the model were converted to multipliers using the formulae of Ara and Brazier \[[@CR39]\], which take into account the age- and gender-distribution relative to the study population.

In order to derive the condition-specific utility values for the model health states and adverse events, a multiplicative approach was used considering multipliers defined according to different health states and adverse events.

Costs and Resource Utilization {#Sec9}
------------------------------

This model considered only direct medical costs including those associated with drug acquisition, general practitioner (GP) visits and specialist visits, examinations, and hospitalizations. This model is set in the Italian NHS perspective. Therefore, only the costs directly reimbursed by the NHS were considered. Since a 5-year time horizon was set, a discounting of 0.035% was applied.

Drug costs were calculated based on prices listed on the Italian Drug Agency website \[[@CR40]\]. For generic drugs, the authors considered prices reimbursed by the NHS, whereas for ASE, the only branded drug, the authors considered the public price applying a discount for NHS (12.5% for drugs between €103.29 and €154.94) after VAT. Treatment doses used in the analysis were the weighted average of the daily doses found in literature. The unit costs per mg, daily doses (mg), and daily costs for the drugs used in this model are reported in Table [3](#Tab3){ref-type="table"}.Table 3Treatment costs considering daily doses from literature and summary of product characteristics (SPCs)TreatmentUnit cost per mg (€)Daily dose (mg)Daily cost (€)Treatment costs considering daily doses from literature Asenapine0.2218.34.07 Olanzapine0.1614.82.39 Quietiapine0.003613.82.05 Valproate0.000041,735.40.68 Lithium0.000021,126.30.19 Lithium + Valproate----0.87TreatmentDaily dose (mg)Daily cost (€)AcuteMaintenanceAcuteMaintenanceTreatment costs considering daily doses from SPCs Asenapine20104.452.22 Olanzapine15102.411.61 Quietiapine--600--2.00 Valproate1,5001,5000.590.59 Lithium1,2001,2000.200.20 Lithium + Valproate----0.790.79

In order to test the dosages applied in the model, the authors developed a scenario analysis adopting the recommended daily doses from the summary of product characteristics (SPCs) for both the acute phase and the maintenance phase (Table [3](#Tab3){ref-type="table"}).

Resource utilization was differentiated according to drug regimen and for the acute and maintenance phases, and it was assessed to reflect the Italian standard clinical practice.

Full blood count, liver panel, blood urea, creatinine, thyroid function (i.e., thyroid-stimulating hormone), serum Li concentration, electrocardiogram, electrolytes, glucose test, lipid profile, prolactin, serum valproic acid concentration, amylase, and ammonium were considered and their costs were taken from the 2014 pricelist from Italian Ministry of Health website (Tariffa Unica Convenzionale \[TUC\]) \[[@CR41]\].

Health state associated costs were estimated to differ on a yearly base and depending upon the episode type (i.e., acute manic, mixed, and depressive episode) and health state. The assumptions of health state costs follow the ones described by Soares-Weiser et al. \[[@CR30]\] and adopted also in the UK model \[[@CR27]\]. Since the Soares-Weiser approach classified services based on the type of management (inpatient, outpatient, and crisis resolution team), the authors readapted this approach to the Italian context (Table [4](#Tab4){ref-type="table"}) introducing Day Hospital service. Furthermore, an adjunctive scenario analysis using a different management breakdown discussed by the expert panel was performed (Table [4](#Tab4){ref-type="table"}). Since Soares-Weiser et al. \[[@CR30]\] reported information on mania and depression only, the authors assumed the same management breakdown and healthcare services utilization for mixed episode and mania.Table 4Management breakdown by Soares-Weiser et al. \[[@CR30]\], from expert opinion and costs for healthcare servicesManagementDepressionMania/mixed episodeManagement breakdown by Soares-Weiser Day hospital20%20% Hospitalization10%80% Outpatient70%--Management breakdown from expert opinion Day hospital20%30% Hospitalization20%70% Outpatient60%--Healthcare serviceCost (€)Stable all yearMania/mixed episodeDepressive episodeHospitalizationDay hospitalHospitalizationDay hospitalOutpatientCosts for healthcare services Psychiatric consultant12.91600004 GP visit14.57600002 Hospitalization2,597.93010100 Day hospital158.79002/3 days a week01 day in a week0*GP* general practitioner

Healthcare services costs and utilizations are presented in Table [4](#Tab4){ref-type="table"} and unit costs were retrieved from the TUC 2014. The authors assumed that the cost for the stable health state is the baseline cost and any relapse event represents an additional cost.

As mentioned before, the main adverse events for patients on treatment for bipolar I disorder are weight gain and EPS. The weight gain costs for the acute phase were a dietician visit cost and an additional GP visit cost; no cost was associated to weight gain in the maintenance phase. For EPS only medication costs (biperidene 6 mg daily for 3 months) were considered, both in acute and maintenance phases.

Cost-Effectiveness and Sensitivity Analyses {#Sec10}
-------------------------------------------

Cost-effectiveness analysis (CEA) is a method for assessing the health gains in relation with the costs of the different health interventions.

The main outcomes of the model are mean costs and QALYs for treatment strategies and the ICERs, which are the observed differences in costs divided by differences in outcomes between two alternative programs. The ICER should be interpreted as the additional cost required to gain an additional unit of health outcome (i.e., QALY) when providing one treatment rather than another one.

The associated probabilities, as long as treatment costs, are subject to uncertainty, so it may be necessary to test robustness of the results obtained changing the model inputs or using alternative parameters. In order to test the robustness of the model results, sensitivity analyses, scenario analyses, and probabilistic analysis were performed.

Based on input from the expert panel, the following analyses were developed:Scenario analysis on different drugs doses;Scenario analysis on different episode management breakdown;Sensitivity analysis on transition probability from non-responder to subacute state;Sensitivity analysis on transition probability from subacute state to stable state.

Furthermore, a probabilistic sensitivity analysis (PSA), in which all model parameters have been varied simultaneously, was also performed.

Results {#Sec11}
=======

Base Case Analysis {#Sec12}
------------------

Table [5](#Tab5){ref-type="table"} presents the results of the base case cost-effectiveness analysis. ASE generated an increase in QALYs of 0.0240 at average lower total costs (i.e., €461.3 less) versus OLA, dominating its comparator. Although the incremental treatment costs (€1,134.5) are greater for ASE than for OLA, savings in health state costs generated by avoiding hospitalization (€1,588.8) offset the total difference (Table [5](#Tab5){ref-type="table"}).Table 5Base case resultsStrategyQALYs w/o AEsQALYs w/AEsTreatment costs (€)AE costs (€)Health state costs (€)Total costs (€)Base case results ASE strategy3.68263.64954,716.286.828,107.932,911.0 OLA strategy3.67203.62563,581.793.929,696.733,372.3 Incremental0.01060.02401,134.5−7.1−1,588.8−461.3Base case results considering only the acute phase (9 weeks) ASE strategy0.08590.0833119.219.418,471.718,610.3 OLA strategy0.08180.078885.131.619,559.119,675.7 Incremental0.00410.004534.1−12.2−1,087.4−1,065.4*AEs* adverse events, *ASE* asenapine, *OLA* olanzapine, *QALYs* quality-adjusted life years, *w/* with, *w/o* without

An incremental gain of 0.0106 QALYs is observed when the impact of adverse events is excluded from quality of life calculations. Also on this outcome, ASE dominates OLA in our cost-effectiveness model (Table [5](#Tab5){ref-type="table"}).

When only the acute phase is considered (Table [5](#Tab5){ref-type="table"}), referring to the first 9 weeks of treatment after the mixed episode, ASE generates greater benefits than OLA (0.0045 more QALYs and 0.0041 more QALYs when the impact of adverse events is excluded) at lower costs (€1,065.4 less). This result indicates that the incremental QALYs and savings are derived largely from the earlier response to treatment during the acute phase.

Scenario Analyses {#Sec13}
-----------------

Table [6](#Tab6){ref-type="table"} describes the results of the scenario analysis on different drug doses in which the average doses derived from clinical studies used in the base case were changed to the daily doses from the SPCs (see Table [3](#Tab3){ref-type="table"}).Table 6Scenario analysesStrategyQALYs w/o AEsQALYs w/AEsTreatment costs (€)AE costs (€)Health state costs (€)Total costs (€)Scenario analysis on different drugs doses ASE strategy3.68263.64953,404.786.828,107.931,599.4 OLA strategy3.67203.62562,982.593.929,696.732,773.1 Incremental0.01060.0240422.2−7.1−1,588.8−1,173.7Scenario analysis on different episode management breakdown ASE strategy3.68843.65534,710.786.826,422.231,219.7 OLA strategy3.67883.63223,577.093.927,857.531,528.4 Incremental0.00960.02311,133.7−7.1−1,435.3−308.6*AEs* adverse events, *ASE* asenapine, *OLA* olanzapine, *QALYs* quality-adjusted life years, *w/* with, *w/o* without

Compared to OLA, also here ASE dominates OLA, with a lower incremental total cost (€1,173.7 less than OLA), with respect to the base case analysis (€461.3 less than OLA) thanks to savings in the treatment costs (€422.2 vs. €1,134.5, respectively).

The results of the scenario analysis on the episodes management breakdown as derived from the experts' opinions rather than the one used in the base case analysis (see Table [4](#Tab4){ref-type="table"}) are described in Table [6](#Tab6){ref-type="table"}. Costs generated by ASE and OLA are slightly lower than the ones of the base case analysis (€31,219.7 and €31,528.4, respectively) due to savings in health state costs. The consistency of results between the base case and the two scenario analyses supports the robustness of the model.

Sensitivity Analyses {#Sec14}
--------------------

A sensitivity analysis on the probability of changing health state from non-responders to subacute health state during the maintenance phase was performed. In the base case analysis, this probability was set at 35% per cycle, while the sensitivity analyses used a probability of 0% and 100%. Results appeared sensitive to variations in this parameter, but ASE remained dominant over OLA throughout the entire range tested by the sensitivity analysis (Table [7](#Tab7){ref-type="table"}).Table 7Sensitivity analysesStrategyQALYs w/AEsTotal costs (€)0% probability of reaching the subacute health state from the non-responders state ASE strategy3.162262,597.7 OLA strategy3.061968,172.8 Incremental0.1003−5,575.1100% probability of reaching the subacute health state from the non-responders state ASE strategy3.666031,887.2 OLA strategy3.644732,178.1 Incremental0.0213−290.90% probability of reaching the stable health state from the subacute health state ASE strategy3.648934,039.6 OLA strategy3.624534,671.2 Incremental0.0244−631.6100% probability of reaching the stable health state from the subacute health state ASE strategy3.649832,409.8 OLA strategy3.626032,795.5 Incremental0.0238−385.7*AEs* adverse events, *ASE* asenapine, *OLA* olanzapine, *QALYs* quality-adjusted life years, *w/* with

Another sensitivity analysis was performed on the probability of reaching the stable health state from the subacute health state. In this analysis the probability was changed from the 60% in the base case analysis to a range from 0% to 100%. Also in this case ASE remained dominant over OLA, similarly to the results obtained in the base case analysis (Table [7](#Tab7){ref-type="table"}).

Probabilistic Sensitivity Analyses {#Sec15}
----------------------------------

In the PSA, the probabilities of response, relapse, discontinuation, and death, the health state utility values and the unit costs were probabilistically sampled 1,000 times generating 1,000 samples.

Figure [3](#Fig3){ref-type="fig"} represents the cost-effectiveness plane in which the 1,000 estimates of mean costs and mean effectiveness resulted from the samples are plotted. In the majority of samples, treatment with ASE resulted to be associated with lower costs and increased QALYs compared to OLA (lower-right quadrant).Fig. 3PSA Scatter plot on cost-effectiveness plane for treatment with ASE versus OLA. *ASE* asenapine, *OLA* olanzapine, *PSA* probabilistic sensitivity analysis, *QALYs* quality-adjusted life years

The higher-right quadrant represents samples that should need money investment in order to achieve additional QALYs by using ASE. In this study, due to the lack of official willingness to pay threshold in Italy, we decided to use an ICER threshold of €30,000 per QALY, slightly lower than the one recognized by the National Institute for Health and Care Excellence (NICE; £20,000--30,000) \[[@CR42]\].

Being so, with a willingness-to-pay threshold set to €30,000 per QALY, treatment of patients experiencing a mixed episode with ASE has a probability of 72.4% to be cost-effective compared to OLA. PSA results also demonstrate that ASE is dominant in 63.1% of simulations.

Discussion {#Sec16}
==========

In our pharmacoeconomic model, developed to simulate the management of bipolar I patients with mixed episodes over a 5-year time period from the Italian NHS perspective, ASE results superior to OLA. In fact, ASE is associated with lower direct costs (−€461.3), derived largely by the savings from hospitalizations avoided (−€1,588.8), and also generates a better quality of life (+ 0.0240 QALYs). In line with results obtained in clinical trials \[[@CR18], [@CR20]\], this pharmacoeconomic study shows that the greater health benefits and cost savings were driven by earlier response to ASE treatment during the acute phase and were well maintained during long-term follow-up.

Results were robust to changes in key parameters; both scenario analyses modeling different health status transition probabilities, drug doses, and episode management breakdown, and sensitivity analyses demonstrated model reliability, being these scenario cases results comparable to base case analysis. In particular, 63.1% out of the 1,000 PSA simulations found that ASE dominated OLA and 72.4% showed an ICER lower than €30,000.

Hospitalizations generate the most important costs, which account for about 85--90% of total expenses and, as highlighted by Brunelle et al. \[[@CR43]\], this burden increases because inpatients that experienced a bipolar I mixed episode may have a prolonged hospitalization.

Results of the original model developed by Sawyer et al. \[[@CR27]\] are slightly different, with ASE not dominating OLA, but generating an ICER value (£1,302) lower than the one usually applied by NICE \[[@CR42]\]. Different results are mostly attributable to the different inpatient and outpatient management between the two Countries, as already described in the method section.

A recent cost-effectiveness analysis performed by Lachaine et al. \[[@CR28]\] in Canada, which focused on metabolic changes and their complications on quality of life and survival, showed a dominance of ASE in comparison with OLA in both NHS and societal perspectives, with an increase of 84.84 QALYs and a cost decrease of 3,847,300 Canadian dollars (for NHS perspective, while for societal perspective is 3,878,343 Canadian dollars) per 1,000 patients.

The foremost strength of this study is the analysis methodology itself, since CEA accounts not only for effectiveness and costs, but includes also information on relapses, hospitalizations, and adverse events. The role of pharmacoeconomic models is central when it is necessary to establish priorities in the allocation of resources in a specific therapeutic area. Indeed, they supply decision makers within healthcare systems with useful tools to make more rational and effective decisions.

The main study limitation concerns the lack of publications regarding ASE treatment of bipolar I type with mixed episode patients, and adequate comparative data for other SGAs in acute phase. In previous meta-analysis \[[@CR14], [@CR44]\] only post hoc analyses on pooled data from clinical trials by McIntyre \[[@CR18]--[@CR20]\] were found comparing ASE and OLA in mixed episodes. Therefore, the authors of this pharmacoeconomic study, similarly to the authors of the previous pharmacoeconomic study performed in the UK \[[@CR27]\], used the post hoc analyses by Azorin et al. \[[@CR17]\] to derive the efficacy and safety of treatments. The model was validated by expert opinions.

Whilst important basic values, such as efficacy and safety of OLA and ASE, were available from these post hoc analyses, evidence for other important parameters, i.e. efficacy of adjunctive therapies, longer-term efficacy of SGAs in relapse prevention, was not available. Therefore, to minimize possible bias, treatment efficacy of combination treatments was assumed to be equal between ASE and OLA, and assumption was made that, during maintenance, in mixed episodes patients efficacy in relapse prevention was similar for both treatments arms.

Model robustness was tested using both deterministic and probabilistic sensitivity analyses; results proved the model reliability.

Another possible limitation could be that only EPS and weight gain has been considered among possible SGAs adverse events. Nevertheless, since ASE showed a better safety profile compared to OLA with regard to metabolic effects including dyslipidemia and type 2 diabetes mellitus \[[@CR45]\], the impact of other adverse events could possibly generate a better performance for ASE.

Conclusion {#Sec17}
==========

Results from this study suggest that the management of bipolar I patients with mixed episodes using ASE as alternative to OLA can lead to cost savings for Italian NHS and improve patients' quality of life. Future researches specifically developed for this subset of patients are needed to fill the gap of information that are required by the cost-effectiveness model and to permit the comparison of ASE with other SGAs.
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